- PII
- S30345057S2686738925020159-1
- DOI
- 10.7868/S3034505725020159
- Publication type
- Article
- Status
- Published
- Authors
- Volume/ Edition
- Volume 521 / Issue number 1
- Pages
- 253-259
- Abstract
- To search for substances selectively acting on tumor cells, phenotypic screening in a coculture of tumor cells with non-tumor cells was used in the work. The compound STOCK7S-36520, selectively cytotoxic in the coculture of breast tumor cells MCF7’ and non-tumor MCF10A, contains structural elements characteristic of kinase inhibitors. Analyzing the compound STOCK7S-36520 and its derivative STOCK7S-47016, it turned out that they are new multikinase inhibitors. The highest inhibition of 84% was shown by compound STOCK7S-47016 against GCK kinase. Of interest is the significant selectivity of action against some of the cell lines studied: the selectivity index of STOCK7S-36520 against the prostate tumor cell line PC3 is 29 times compared to the model line of non-tumor fibroblasts VA13.
- Keywords
- цитотоксичность противоопухолевые препараты ингибиторы киназ FCCT-тест селективность
- Date of publication
- 15.04.2025
- Year of publication
- 2025
- Number of purchasers
- 0
- Views
- 61
References
- 1. Jaffee, E.M., C.V. Dang, D.B. Agus, et al., Future cancer research priorities in the USA: a Lancet Oncology Commission // Lancet Oncol, 2017. 18(11): P. e653-e706.
- 2. Seebacher, N. A., A.E. Stacy, G.M. Porter, et al., Clinical development of targeted and immune based anti-cancer therapies. // J Exp Clin Cancer Res, 2019. 38(1): P. 156.
- 3. Levitzki, A. and S. Klein, My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer. // Proc Natl Acad Sci USA, 2019. 116(24): P. 11579-11586.
- 4. Sadri, A., Is Target-Based Drug Discovery Efficient? Discovery and “Off-Target” Mechanisms of All Drugs // J Med Chem, 2023. 66(18): P. 12651-12677.
- 5. Ediriweera, M.K., K.H. Tennekoon, and S.R. Samarakoon, In vitro assays and techniques utilized in anticancer drug discovery. // J Appl Toxicol, 2019. 39(1): P. 38-71.
- 6. Cagan, R., Drug screening using model systems: some basics. // Dis Model Mech, 2016. 9(11): P. 1241-1244.
- 7. Spink, B.C., R.W. Cole, B.H. Katz, et al., Inhibition of MCF-7 breast cancer cell proliferation by MCF-10A breast epithelial cells in coculture. // Cell Biol Int, 2006. 30(3): P. 227-38.
- 8. Skvortsov, D.A., M.A. Kalinina, I.V. Zhirkina, et al., From Toxicity to Selectivity: Coculture of the Fluorescent Tumor and Non-Tumor Lung Cells and High-Throughput Screening of Anticancer Compound. // Front. Pharmacol., 2021. 12: P. 1-11.
- 9. Xing, L., J. Klug-Mcleod, B. Rai, et al., Kinase hinge binding scaffolds and their hydrogen bond patterns. // Bioorg Med Chem, 2015. 23(19): P. 6520-7.
- 10. Cohen, P., D. Cross, and P.A. Janne, Kinase drug discovery 20 years after imatinib: progress and future directions. // Nat Rev Drug Discov, 2021. 20(7): P. 551-569.
- 11. Kalinina, M.A., D.A. Skvortsov, M.P.Rubtsova, et al., Cytotoxicity Test Based on Human Cells Labeled with Fluorescent Proteins: Fluorimetry, Photography, and Scanning for High-Throughput Assay. // Mol Imaging Biol, 2018. 20(3): P. 368-377.
- 12. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays // J Immunol Methods, 1983. 65(12): P. 55-63.
- 13. Brenchley, G., L.j. Farmer, E.M. Harrington, et al. Thiazoles useful as inhibitors of protein kinases.2003 Last Update [cited Access 2003; Edition:[Description].
- 14. Andersen, C.B., Y. Wan, J.W. Chang, et al., Discovery of selective aminothiazole aurora kinase inhibitors. // ACS Chem Biol, 2008. 3(3): P. 180-92.
- 15. Skvortsov, D., I. Zhirkina, M. Kalinina, et al. Application of indenofluorene derivative for inhibition and/ or elimination of tumor cells.2023 Last Update [cited Access 2023; Edition:[Description].
- 16. Weisberg, E., P. Manley, J. Mestan, et al., AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. // Br J Cancer, 2006. 94(12): P. 1765-9.
- 17. Manley, P.W., P. Drueckes, G. Fendrich, et al., Extended kinase profile and properties of the protein kinase inhibitor nilotinib. // Biochim Biophys Acta, 2010. 1804(3): P. 445-53.
- 18. Tsherniak, A., F. Vazquez, P.G. Montgomery, et al., Defining a Cancer Dependency Map. // Cell, 2017. 170(3): P. 564-576 e16.
